Fox Matthew P, Rosen Sydney
aCenter for Global Health & Development, Boston University bDepartment of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA cHealth Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
AIDS. 2015 Feb 20;29(4):493-502. doi: 10.1097/QAD.0000000000000559.
There are several published systematic reviews of adult retention in care after antiretroviral therapy (ART) initiation among adults, but limited information on pediatric retention.
Systematic review of pediatric retention on ART in low and middle-income countries during 2008-2013.
We estimated all-cause attrition (death and loss to follow-up) and retention for pediatric patients receiving first-line ART in routine settings. We searched PubMed, Embase, Cochrane Register, and ISI Web of Science (January 2008-January 2014) and abstracts from AIDS and IAS (2008-2013). We estimated mean retention across cohorts using simple averages; interpolated any time period not reported to, up to the last period reported; summarized total retention in the population using Kaplan-Meier survival curves; and compared pediatric to adult retention.
We found 39 reports of retention in 45 patient cohorts and 55 904 patients in 23 countries. Among them, 37% of patients not retained in care were known to have died and 63% were lost to follow-up. Unweighted averages of reported retention were 85, 81, and 81% at 12, 24, and 36 months after ART initiation. From life-table analysis, we estimated retention at 12, 24, and 36 months at 88, 72, and 67%. We estimated 36-month retention at 66% in Africa and 74% in Asia.
Pediatric ART retention was similar to that among adults. There were limited data from Asia, only one study from Latin America and the Caribbean, and no data from Eastern Europe, Central Asia, or the Middle East.
已有多篇关于成人开始抗逆转录病毒治疗(ART)后在治疗中留存情况的系统评价,但关于儿童留存情况的信息有限。
对2008 - 2013年期间低收入和中等收入国家儿童接受ART治疗的留存情况进行系统评价。
我们估计了在常规环境中接受一线ART治疗的儿科患者的全因损耗(死亡和失访)及留存情况。我们检索了PubMed、Embase、Cochrane图书馆和科学引文索引(2008年1月 - 2014年1月)以及艾滋病和国际艾滋病学会的摘要(2008 - 2013年)。我们使用简单平均数估计各队列的平均留存率;对未报告的任何时间段进行插值,直至报告的最后时间段;使用Kaplan - Meier生存曲线总结总体人群的总留存率;并比较儿童与成人的留存情况。
我们在23个国家的45个患者队列和55904名患者中发现了39篇关于留存情况的报告。其中,已知未接受治疗的患者中有37%死亡,63%失访。ART开始后12、24和36个月报告的留存率未加权平均值分别为85%、81%和81%。通过生命表分析,我们估计12、24和36个月的留存率分别为88%、72%和67%。我们估计非洲36个月的留存率为66%,亚洲为74%。
儿童ART留存情况与成人相似。来自亚洲的数据有限,拉丁美洲和加勒比地区仅有一项研究,东欧、中亚或中东没有数据。